Serum prostate-specific antigen levels in men with prediabetes: A cross-sectional study

References

• Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol 2003;21:383–91.
   PubMed Web of Science ®Google Scholar
• Liang SL, Chan DW. Enzymes and related proteins as cancer biomarkers: a proteomic approach. Clin Chim Acta 2007;381:93–7.
   PubMed Web of Science ®Google Scholar
• Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CJ. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004;350:2239–46.
   PubMed Web of Science ®Google Scholar
• Müller H, Raum E, Rothenbacher D, Stegmaier C, Brenner H. Association of diabetes and body mass index with levels of prostate-specific antigen: implications for correction of prostate-specific antigen cutoff values? Cancer Epidemiol Biomarkers Prev 2009;18:1350–6.
   PubMed Web of Science ®Google Scholar
• Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus – present and future perspectives. Nat Rev Endocrinol 2011;8:228–36.
   PubMed Web of Science ®Google Scholar
• Zhang PH, Chen ZW, Lv D, Xu YY, Gu WL, Zhang XH, Le YL, Zhu HH, Zhu YM. Increased risk of cancer in patients with type 2 diabetes mellitus: a retrospective cohort study in China. BMC Public Health 2012:doi: 10.1186/471-2458-12-567.
   Google Scholar
• Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. Diabetes Care 2010;33:1674–85.
   PubMed Web of Science ®Google Scholar
• Cohen DH, LeRoith D. Obesity, type 2 diabetes, and cancer: the insulin and IGF connection. Endocr Relat Cancer 2012;19:F27–45.
   PubMed Web of Science ®Google Scholar
• Rhee SY, Woo JT. The prediabetic period: review of clinical aspects. Diabetes Metab J 2011;35:107–16.
   PubMedGoogle Scholar
• Fukui M, Tanaka M, Kadono M, Imai S, Hasegawa G, Yoshikawa T, Nakamura N. Serum prostate-specific antigen levels in men with type 2 diabetes. Diabetes Care 2008; 31:930–1.
   PubMed Web of Science ®Google Scholar
• Werny DM, Saraiya M, Gregg EW. Prostate-specific antigen values in diabetic and nondiabetic US men, 2001–2002. Am J Epidemiol 2006;164:978–83.
   Google Scholar
• Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1992;75:1046–53.
   PubMed Web of Science ®Google Scholar
• Wolk A, Mantzoros CS, Andersson SO, Bergström R, Signorello LB, Lagiou P, Adami HO, Trichopoulos D. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998;90:911–5.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012;35:S64–71.
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15: 539–53.
   PubMed Web of Science ®Google Scholar
• Pallant J. SPSS survival manual: a step by step guide to data analysis using SPSS for windows (version 10 and 11): Open University Press; 2004.
   Google Scholar
• Pierce BL. Why are diabetics at reduced risk for prostate cancer? A review of the epidemiologic evidence. Urol Oncol 2012;30:735–43.
   PubMed Web of Science ®Google Scholar
• Lawrence YR, Morag O, Benderly M, Boyko V, Novikov I, Dicker AP, Goldbourt U, Behar S, Barchana M, Wolf I. Association between metabolic syndrome, diabetes mellitus and prostate cancer risk. Prostate Cancer Prostatic Dis 2013;16: 181–6.
   PubMed Web of Science ®Google Scholar
• Frayling TM, Colhoun H, Florez JC. A genetic link between type 2 diabetes and prostate cancer. Diabetologia 2008;51: 1757–60.
   PubMed Web of Science ®Google Scholar
• Protopsaltis I, Ploumidis A, Sergentanis TN, Constantoulakis P, Tzirogiannis K, Kyprianidou C, Papazafiropoulou AK, Melidonis A, Delakas D. Linking pre-diabetes with benign prostate hyperplasia. IGFBP-3: a conductor of benign prostate hyperplasia development orchestra? PLoS One 2013;8:e81411.
   Google Scholar
• Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM, Martin RM. Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta- analysis. Int J Cancer 2009;124:2416–29.
   PubMed Web of Science ®Google Scholar
• Cohen P, Peehl DM, Graves HC, Rosenfeld RG. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol 1994;142: 407–15.
   PubMed Web of Science ®Google Scholar
• Tande AJ, Platz EA, Folsom AR. The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol 2006;164:1094–102.
   PubMed Web of Science ®Google Scholar
• Hsing AW, Reichardt JK, Stanczyk FZ. Hormones and prostate cancer: current perspectives and future directions. Prostate 2002;52:213–35.
   PubMedGoogle Scholar
• Hsing AW, Sakoda LC, Chua SJ. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 2007;86: s843–57.
   PubMed Web of Science ®Google Scholar
• Onitilo AA, Berg RL, Engel JM, Stankowski RV, Glurich I, Williams GM, Doi SA. Prostate cancer risk in pre-diabetic men: a matched cohort study. Clin Med Res 2013;11:201–9.
   PubMedGoogle Scholar
• Huang Y, Cai X, Qiu M, Chen P, Tang H, Hu Y, Huang Y. Prediabetes and the risk of cancer: a meta-analysis. Diabetologia 2014;57:2261–9.
   PubMed Web of Science ®Google Scholar
• Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993;270:860–4.
   Google Scholar
• Malati T, Kumari GR. Racial and ethnic variation of PSA in global population: age specific reference intervals for serum prostate specific antigen in healthy South Indian males. Indian J Clin Biochem 2004;19:132–7.
   PubMedGoogle Scholar
• Mondul AM, Selvin E, De Marzo AM, Freedland SJ, Platz EA. Statin drugs, serum cholesterol, and prostate-specific antigen in the National Health and Nutrition Examination Survey 2001–2004. Cancer Causes Control 2010;21:671–8.
   PubMed Web of Science ®Google Scholar
• Han JH, Choi NY, Bang SH, Kwon OJ, Jin YW, Myung SC, Chang IH, Kim TH, Ahn SH. Relationship between serum prostate-specific antigen levels and components of metabolic syndrome in healthy men. Urology 2008;72:749–54.
   PubMed Web of Science ®Google Scholar
• Fowke JH, Matthews CM, Buchowski MS, Signorello LB, Chang SS, Cookson MS, Blot WJ. Association between prostate-specific antigen and leptin, adiponectin, HbA1c or C-peptide among African-American and Caucasian men. Prostate Cancer Prostatic Dis 2008;11:264–9.
   PubMed Web of Science ®Google Scholar
• Ohwaki K, Endo F, Muraishi O, Yano E. Relationship between changes in haemoglobin A1C and prostate-specific antigen in healthy men. Eur J Cancer 2011;47:262–6.
   PubMed Web of Science ®Google Scholar
• Herman WH, Cohen RM. Racial and ethnic differences in the relationship between HbA1c and blood glucose: implications for the diagnosis of diabetes. J Clin Endocrinol Metab 2012;97:1067–72.
   PubMed Web of Science ®Google Scholar
• Naito M, Asai Y, Mori A, Fukada Y, Kuwabara M, Katase S, Hishida A, Morita E, Kawai S, Okada R, Nishio K, Tamakoshi A, Wakai K, Hamajima N. Association of obesity and diabetes with serum prostate-specific antigen levels in Japanese males. Nagoya J Med Sci 2012;74:285–92.
   PubMed Web of Science ®Google Scholar
• Djavan B, Bursa B, Seitz C, Soeregi G, Remzi M, Basharkhah A, Wolfram R, Marberger M. Insulin-like growth factor 1 (IGF-1), IGF-1 density, and IGF-1/PSA ratio for prostate cancer detection. Urology 1999;54:603–6.
   PubMed Web of Science ®Google Scholar
• Koliakos G, Chatzivasiliou D, Dimopoulos T, Trachana V, Paschalidou K, Galiamoutsas V, Triantos A, Chitas G, Dimopoulos A, Vlatsas G. The significance of PSA/IGF-1 ratio in differentiating benign prostate hyperplasia from prostate cancer. Dis Markers 2000;16:143–6.
   PubMed Web of Science ®Google Scholar